123 related articles for article (PubMed ID: 30473754)
1. Correction: Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells.
Novohradsky V; Zajac J; Vrana O; Kasparkova J; Brabec V
Oncotarget; 2018 Oct; 9(85):35599. PubMed ID: 30473754
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells.
Novohradsky V; Zajac J; Vrana O; Kasparkova J; Brabec V
Oncotarget; 2018 Jun; 9(47):28456-28473. PubMed ID: 29983873
[TBL] [Abstract][Full Text] [Related]
3. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
4. Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.
Borst GR; Kumareswaran R; Yücel H; Telli S; Do T; McKee T; Zafarana G; Jonkers J; Verheij M; O'Connor MJ; Rottenberg S; Bristow RG
Oncotarget; 2020 Apr; 11(17):1573-1574. PubMed ID: 32391125
[TBL] [Abstract][Full Text] [Related]
5. Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing rats.
Shi M; Anantha M; Wehbe M; Bally MB; Fortin D; Roy LO; Charest G; Richer M; Paquette B; Sanche L
J Nanobiotechnology; 2018 Oct; 16(1):77. PubMed ID: 30290821
[TBL] [Abstract][Full Text] [Related]
6. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
7. Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.
Lee JM; Hays JL; Chiou VL; Annunziata CM; Swisher EM; Harrell MI; Yu M; Gordon N; Sissung TM; Ji J; Figg WD; Minasian L; Lipkowitz S; Wood BJ; Doroshow J; Kohn EC
Oncotarget; 2017 Oct; 8(45):79175-79187. PubMed ID: 29108297
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
van der Noll R; Marchetti S; Steeghs N; Beijnen JH; Mergui-Roelvink MW; Harms E; Rehorst H; Sonke GS; Schellens JH
Br J Cancer; 2015 Jul; 113(3):396-402. PubMed ID: 26180927
[TBL] [Abstract][Full Text] [Related]
9. Ligand peptide-grafted PEGylated liposomes using HER2 targeted peptide-lipid derivatives for targeted delivery in breast cancer cells: The effect of serine-glycine repeated peptides as a spacer.
Suga T; Fuchigami Y; Hagimori M; Kawakami S
Int J Pharm; 2017 Apr; 521(1-2):361-364. PubMed ID: 28237886
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple‑negative breast cancer cells.
Zhao H; Yang Q; Hu Y; Zhang J
Oncol Rep; 2018 Dec; 40(6):3223-3234. PubMed ID: 30272286
[TBL] [Abstract][Full Text] [Related]
11. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
14. Correction: Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer.
Guido BC; Brandão DC; Barbosa ALA; Vianna MJX; Faro L; Ramos LM; Nihi F; de Castro MB; Neto BAD; Corrêa JR; Báo SN
Oncotarget; 2022; 13():1068. PubMed ID: 36187557
[TBL] [Abstract][Full Text] [Related]
15. PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Shavi GV; Sreenivasa Reddy M; Raghavendra R; Nayak UY; Kumar AR; Deshpande PB; Udupa N; Behl G; Dave V; Kushwaha K
J Liposome Res; 2016; 26(1):28-46. PubMed ID: 25853340
[TBL] [Abstract][Full Text] [Related]
16. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
[TBL] [Abstract][Full Text] [Related]
17. Correction: Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget.
Qiu YQ; Yang CW; Lee YZ; Yang RB; Lee CH; Hsu HY; Chang CC; Lee SJ
Oncotarget; 2019 Aug; 10(47):4919. PubMed ID: 31448057
[TBL] [Abstract][Full Text] [Related]
18. Correction: A tissue factor-cascade-targeted strategy to tumor vasculature: a combination of EGFP-EGF1 conjugation nanoparticles with photodynamic therapy.
Shi W; Yin Y; Wang Y; Zhang B; Tan P; Jiang T; Mei H; Deng J; Wang H; Guo T; Pang Z; Hu Y
Oncotarget; 2018 Apr; 9(25):17979. PubMed ID: 29707163
[TBL] [Abstract][Full Text] [Related]
19. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E
Gynecol Oncol; 2011 Aug; 122(2):226-32. PubMed ID: 21575983
[TBL] [Abstract][Full Text] [Related]
20. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.
Judge A; McClintock K; Phelps JR; Maclachlan I
Mol Ther; 2006 Feb; 13(2):328-37. PubMed ID: 16275098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
